Valuation: Unicycive Therapeutics, Inc.

Market Cap 135M 119M 111M 102M 191M 12.96B 195M 1.32B 515M 6.41B 508M 497M 22.17B P/E 2026 *
-3.49x
P/E 2027 * 0.96x
Enterprise Value 135M 119M 111M 102M 191M 12.96B 195M 1.32B 515M 6.41B 508M 497M 22.17B EV / Sales 2026 *
35.6x
EV / Sales 2027 * 0.47x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 46.6%
1 day-2.73%
1 week-13.29%
Current month+2.99%
1 month-37.27%
3 months-32.54%
6 months-27.59%
Current year-16.29%
1 week 4.79
Extreme 4.79
5.61
1 month 3.93
Extreme 3.93
5.93
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
33.8
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
5/14/26 A Free

Chief Operating Officer

169,500 0.6716%
5/14/26 A Free

Chief Financial Officer

169,500 0.6716%
5/14/26 A Free

Chief Executive Officer

762,200 3.0201%
Change 5-day change 1-year change 3-year change Capi.($)
-3.54%-13.29%+9.28%-58.72% 135M
+0.47%+2.27%+50.78%+69.72% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+1.06%+2.52%-15.55%-13.53% 23.38B
-0.98%-2.03%-0.50%+372.97% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%-2.30%+27.27%-33.01% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-1.78%+1.93%+51.71%+184.32% 14.2B
Average -0.42%-1.82%+37.51%+142.42% 23.73B
Weighted average by Cap. +0.54%-0.21%+37.60%+129.47%

Financials

2026 *2027 *
Net sales 3.8M 3.34M 3.12M 2.86M 5.36M 364M 5.49M 37M 14.47M 180M 14.28M 13.97M 623M 288M 253M 237M 217M 406M 27.62B 416M 2.8B 1.1B 13.67B 1.08B 1.06B 47.25B
Net income -40.34M -35.44M -33.08M -30.36M -56.84M -3.86B -58.24M -392M -153M -1.91B -151M -148M -6.61B 186M 164M 153M 140M 262M 17.83B 269M 1.81B 708M 8.83B 699M 684M 30.51B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
29/07/26 $4.820 -2.43% 1,228,684
28/07/26 $4.940 -3.70% 1,008,224
27/07/26 $5.130 -5.00% 632,539
24/07/26 $5.400 -1.10% 497,709
23/07/26 $5.460 -1.97% 649,585
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.940USD
Average target price
38.59USD
Spread / Average Target
+681.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock